Description

Palbociclib 125 mg

Palbociclib 125 mg is a prescription CDK4/6 inhibitor used in combination with endocrine therapy for the treatment of certain types of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer.

Palbociclib works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), proteins that regulate cell-cycle progression. By blocking these proteins, palbociclib can slow the growth and multiplication of certain breast cancer cells.

Product Information

Product Name	Palbociclib 125 mg
Generic Name	Palbociclib
Strength	125 mg
Drug Class	CDK4/6 Inhibitor
Therapeutic Use	HR-positive, HER2-negative Breast Cancer
Dosage Form	Capsule / Tablet, depending on product
Route of Administration	Oral
Prescription Status	Prescription Medicine

Uses of Palbociclib 125 mg

Palbociclib may be prescribed for certain patients with:

• HR-positive, HER2-negative advanced or metastatic breast cancer

• Advanced breast cancer in combination with an aromatase inhibitor

• Advanced or metastatic breast cancer in combination with fulvestrant following progression on endocrine therapy

In appropriate patients, it may also be used with an aromatase inhibitor or fulvestrant alongside ovarian suppression in premenopausal or perimenopausal women.

The exact treatment regimen depends on the patient’s cancer characteristics, previous treatments, menopausal status, and oncologist’s assessment.

How Palbociclib 125 mg Works

Palbociclib selectively inhibits CDK4 and CDK6.

These enzymes help regulate the transition of cells from the G1 phase to the S phase of the cell cycle. By inhibiting CDK4/6 activity, palbociclib can prevent certain cancer cells from progressing through the cell cycle and multiplying.

This mechanism helps slow the growth of susceptible breast cancer cells.

Benefits of Palbociclib 125 mg

• Helps slow the progression of certain breast cancers

• Targets CDK4/6 pathways involved in cancer-cell proliferation

• Used with endocrine therapy for HR-positive, HER2-negative advanced or metastatic breast cancer

• Provides a targeted treatment approach for appropriately selected patients

Directions for Use

Take palbociclib exactly as prescribed by your oncologist.

The standard palbociclib regimen is 125 mg once daily for 21 consecutive days followed by 7 days without treatment, forming a 28-day cycle. Your doctor may reduce the dose or modify the treatment schedule depending on side effects, blood counts, liver function, and other factors.

Swallow the medicine whole with water. Do not crush, chew, or open the capsule unless the specific formulation’s instructions permit it.

Take it at approximately the same time each day.

If you miss a dose or vomit after taking a dose, do not take an additional dose unless instructed by your healthcare team.

Possible Side Effects

Common side effects may include:

• Neutropenia

• Leukopenia

• Anemia

• Thrombocytopenia

• Fatigue

• Nausea

• Mouth sores

• Diarrhea

• Decreased appetite

• Hair thinning or hair loss

• Infections

• Abnormal liver-function tests

Neutropenia is one of the most common adverse effects and may increase the risk of infection.

Serious Side Effects

Palbociclib can cause serious adverse effects, including:

• Severe neutropenia

• Serious infections

• Febrile neutropenia

• Interstitial lung disease or pneumonitis

• Significant blood-count abnormalities

Contact your healthcare team promptly if you develop fever, chills, persistent cough, difficulty breathing, or other signs of infection.

Precautions

Before starting palbociclib, inform your oncologist if you have liver disease, a history of lung disease, recurrent infections, or other significant medical conditions.

Regular monitoring may include:

• Complete blood counts

• Liver-function tests

• Assessment for signs of infection

• Evaluation of treatment response and adverse effects

Palbociclib is metabolized primarily through CYP3A. Strong CYP3A inhibitors and inducers can significantly affect palbociclib levels. Tell your doctor about all medicines, supplements, and herbal products you take.

Avoid grapefruit and grapefruit juice unless your healthcare professional specifically advises that they are safe during treatment.

Frequently Asked Questions

What is Palbociclib 125 mg used for?

Palbociclib 125 mg is used with endocrine therapy for certain patients with HR-positive, HER2-negative advanced or metastatic breast cancer.

What type of medicine is Palbociclib?

Palbociclib is a targeted anticancer medicine belonging to the CDK4/6 inhibitor class.

How does Palbociclib 125 mg work?

It blocks CDK4 and CDK6 proteins involved in cell-cycle progression. This can prevent certain breast cancer cells from multiplying and slow tumor growth.

How is Palbociclib 125 mg normally taken?

The standard regimen is 125 mg once daily for 21 days followed by 7 days off treatment, making a 28-day cycle. Your oncologist may adjust this regimen based on your individual circumstances.

Can Palbociclib be taken alone?

Palbociclib is generally used in combination with endocrine therapy rather than as a standalone treatment for the approved breast cancer indications.

Does Palbociclib cause low white blood cells?

Yes. Neutropenia and other reductions in blood-cell counts are common with palbociclib, which is why regular blood tests are important during treatment.

Can Palbociclib cause infections?

Yes. Reduced neutrophil counts can increase the risk of infection. Report fever, chills, or other signs of infection to your healthcare team promptly.

Can Palbociclib cause hair loss?

Hair thinning or hair loss can occur, although the severity varies between individuals.

Can Palbociclib be taken during pregnancy?

Palbociclib can cause fetal harm. Patients who could become pregnant should discuss effective contraception and pregnancy precautions with their healthcare professional before and during treatment.

Is Palbociclib 125 mg a prescription medicine?

Yes. Palbociclib is a prescription anticancer medicine and should be used under the supervision of an oncologist or other qualified healthcare professional.